person · Reporting owner

Lappe Mark

Disclosed activity across 2 companies

Tapewire entity: 87508
SEC CIK: 0001366074

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Inhibrx Biosciences, Inc.INBX · Entity 4576	Director · Chief Executive Officer	October 14, 2026	October 14, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Inhibrx Biosciences, Inc.

Report date October 14, 2026 · Filed October 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy the Lappe Family Trust	745,588	Last balance in matching sequence After 2026-10-14 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2026-10-14 · Purchase · Acquired 2,470 · Balance 743,018 F1: The shares were purchased in multiple transactions at prices ranging from $83.61 to $84.59 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Row 2 · 2026-10-14 · Purchase · Acquired 2,470 · Balance 745,488 F3: The shares were purchased in multiple transactions at prices ranging from $84.65 to $85.62 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Row 3 · 2026-10-14 · Purchase · Acquired 100 · Balance 745,588 F2: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust.
Common StockSEC Table I · non-derivative	IndirectBy Lappe Descendants' Trust	170,000	Last balance in matching sequence After 2026-10-14 transaction · row 6 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 4 · 2026-10-14 · Purchase · Acquired 2,449 · Balance 167,449 F1: The shares were purchased in multiple transactions at prices ranging from $83.61 to $84.59 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F4: These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust. Row 5 · 2026-10-14 · Purchase · Acquired 2,451 · Balance 169,900 F3: The shares were purchased in multiple transactions at prices ranging from $84.65 to $85.62 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F4: These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust. Row 6 · 2026-10-14 · Purchase · Acquired 100 · Balance 170,000 F4: These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust.
Common StockSEC Table I · non-derivative	IndirectThe Mark Paul Lappe Roth IRA	54,865	Reported balance Holding disclosure · report date 2026-10-14 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 54,865

Filing footnotes · ownership attribution and instrument terms

F1: The shares were purchased in multiple transactions at prices ranging from $83.61 to $84.59 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust.

F3: The shares were purchased in multiple transactions at prices ranging from $84.65 to $85.62 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F4: These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Inhibrx, Inc.

Report date May 30, 2024 · Filed May 30, 2024

Section 16 reporting ended · disclosed 2024-05-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy the Lappe Family Trust	Reported balance After 2024-05-30 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2024-05-30 · Disposition to issuer · Disposed 2,486,192 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company. F3: These securities were directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust.
Common StockSEC Table I · non-derivative	IndirectBy trust	Reported balance After 2024-05-30 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2024-05-30 · Disposition to issuer · Disposed 500,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company. F4: These securities were directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust.
Common StockSEC Table I · non-derivative	IndirectThe Mark Paul Lappe Roth IRA	Reported balance After 2024-05-30 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2024-05-30 · Disposition to issuer · Disposed 59,462 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.30 · Expires 2033-01-03	Direct	Reported balance After 2024-05-30 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-05-30 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F6: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer's common stock under such stock option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F5: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 15, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.63 · Expires 2031-01-15	Direct	Reported balance After 2024-05-30 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-05-30 · Disposition to issuer · Disposed 145,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F8: This stock option was canceled in the Merger and converted into the right to receive the contingent payment described in the following sentence. If the Milestone is achieved, the cash amount to be paid in respect of each such stock option will be equal to (x) $35.00 (representing the sum of the Closing Amount of $30.00 and the Milestone Payment of $5.00) minus (y) the option exercise price per share, subject to applicable tax withholding. F7: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 3, 2024, with the balance to vest and become exercisable in equal successive monthly installments thirty-six (36) months thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").

F2: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company.

F3: These securities were directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust.

F4: These securities were directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust.

F5: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 15, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.

F6: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer's common stock under such stock option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option.

F7: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 3, 2024, with the balance to vest and become exercisable in equal successive monthly installments thirty-six (36) months thereafter.

F8: This stock option was canceled in the Merger and converted into the right to receive the contingent payment described in the following sentence. If the Milestone is achieved, the cash amount to be paid in respect of each such stock option will be equal to (x) $35.00 (representing the sum of the Closing Amount of $30.00 and the Milestone Payment of $5.00) minus (y) the option exercise price per share, subject to applicable tax withholding.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 17, 2022 Filed Oct 18, 2022 16:37 UTC	Inhibrx, Inc. INBX · Entity 90351	SaleCommon Stock	121	$31.51	$3,812.36	Disclosure SEC source: 0001739614-22-000107 · wf-form4_166612539476406.xml · nonDerivative · entry 4 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer Lappe Family Trust · CIK 0001821266 · To be Verified Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 2,564,252 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe. F6 · price: The shares were sold in multiple transactions at prices ranging from $31.48 to $31.56, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document
October 17, 2022 Filed Oct 18, 2022 16:37 UTC	Inhibrx, Inc. INBX · Entity 90351	SaleCommon Stock	2,892	$30.81	$89,089.51	Disclosure SEC source: 0001739614-22-000107 · wf-form4_166612539476406.xml · nonDerivative · entry 3 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer Lappe Family Trust · CIK 0001821266 · To be Verified Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 2,564,373 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe. F5 · price: The shares were sold in multiple transactions at prices ranging from $30.48 to $31.44, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document
October 17, 2022 Filed Oct 18, 2022 16:37 UTC	Inhibrx, Inc. INBX · Entity 90351	SaleCommon Stock	14,006	$29.92	$419,122.55	Disclosure SEC source: 0001739614-22-000107 · wf-form4_166612539476406.xml · nonDerivative · entry 2 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer Lappe Family Trust · CIK 0001821266 · To be Verified Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 2,567,265 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe. F4 · price: The shares were sold in multiple transactions at prices ranging from $29.475 to $30.47, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document
October 17, 2022 Filed Oct 18, 2022 16:37 UTC	Inhibrx, Inc. INBX · Entity 90351	SaleCommon Stock	8,981	$28.66	$257,418.81	Disclosure SEC source: 0001739614-22-000107 · wf-form4_166612539476406.xml · nonDerivative · entry 1 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer Lappe Family Trust · CIK 0001821266 · To be Verified Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 2,581,271 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe. F2 · price: The shares were sold in multiple transactions at prices ranging from $28.475 to $29.47, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document
January 15, 2021 Filed Jan 19, 2021 16:10 UTC	Inhibrx, Inc. INBX · Entity 90351	GrantStock Option (right to buy) · Derivative	145,000	$0.00 Strike: $33.63	$0.00	Disclosure SEC source: 0001739614-21-000018 · wf-form4_161109064662411.xml · derivative · entry 4 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer Lappe Family Trust · CIK 0001821266 · To be Verified Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2031-01-15 F3 · derivative.exercise_date: (3) Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on January 15, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document
December 28, 2020 Filed Jan 19, 2021 16:10 UTC	Inhibrx, Inc. INBX · Entity 90351	GiftCommon Stock	500,000	$0.00	$0.00	Disclosure SEC source: 0001739614-21-000018 · wf-form4_161109064662411.xml · nonDerivative · entry 2 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer Lappe Family Trust · CIK 0001821266 · To be Verified Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 500,000 F1 · kind: (1) This transaction involved a gift of securities by the Lappe Family Trust to a trust for the benefit of the reporting person's immediate family. Read SEC document
December 28, 2020 Filed Jan 19, 2021 16:10 UTC	Inhibrx, Inc. INBX · Entity 90351	GiftCommon Stock	500,000	$0.00	$0.00	Disclosure SEC source: 0001739614-21-000018 · wf-form4_161109064662411.xml · nonDerivative · entry 1 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer Lappe Family Trust · CIK 0001821266 · To be Verified Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 2,590,252 F1 · kind: (1) This transaction involved a gift of securities by the Lappe Family Trust to a trust for the benefit of the reporting person's immediate family. F2 · ownership.nature: (2) These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is the trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.